zggs18
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2022 (NCT05584800)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06938880 | Phase 1/Phase 2 (Phase 2) | May 31, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05584800 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2022 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1